Our biomarker-driven approach will
redefine cancer treatment.
- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Therapeutic Areas
- Oncology
- Publications
- Programs
- Pipeline
- mTORC1/2 inhibitor Sapanisertib
- SYK Inhibitor Mivavotinib
- Preclinical Programs
- Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
-
Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution
-
Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update
-
Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
-
Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer
-
Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Targeting cancer, differently.
Targeting cancer, differently.
Our biomarker-driven approach will
redefine cancer treatment.Targeting cancer, differently.
Our biomarker-driven approach will
redefine cancer treatment.Development Pipeline
Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations.
Development Pipeline
Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.
Recent News